EFFICACY OF IMMUNOCORRECTIVE TREATMENT WITH SYNTHETIC DIPEPTIDE IN CHILDREN WITH PYELONEPHRITIS

Abstract

The results of the open controlled prospective clinical and immunological trial indicate that including of pidotimod into the complex therapy of pyelonephritis in children (n=30) lead to reliable decrease of recurrence risk and frequency during 6 months after treatment withdrawal in comparison with children receiving antibacterial monotherapy (n=20). The duration of etiotropic treatment for arresting of the active manifestations of urinary tract infection was lower in patients who were administered the afore-mentioned drug. Immunological monitoring of the urine cytokine status during pidotimod treatment showed that there were signs of T helper 1 cells activation predominance (increase in interferon/interleukin 10 ratio), as well as decrease in granulocyte macrophage colony-stimulating factor concentration, which seems to cause the delayed influence of the drug on the course of urinary tract infection.

Keywords

• children
• pidotimod
• pyelonephritis
• cytokines